ENTRY       D10551                      Drug
NAME        Ceritinib (JAN/USAN/INN);
            Zykadia (TN)
PRODUCT     ZYKADIA (Novartis Pharmaceuticals Corporation)
FORMULA     C28H36ClN5O3S
EXACT_MASS  557.2227
MOL_WEIGHT  558.1351
CLASS       Antineoplastic
             DG01918  Tyrosine kinase inhibitor
              DG03136  ALK inhibitor
            Metabolizing enzyme substrate
             DG01633  CYP3A/CYP3A4 substrate
REMARK      Therapeutic category: 4291
            ATC code: L01ED02
            Product: D10551<JP/US>
EFFICACY    Antineoplastic, Anaplastic lymphoma kinase (ALK) inhibitor
  DISEASE   Non-small cell lung cancer (ALK positive) [DS:H00014]
TARGET      EML4-ALK [HSA_VAR:238v1] [HSA:238] [KO:K05119]
  PATHWAY   hsa05200(238)  Pathways in cancer
            hsa05223(238)  Non-small cell lung cancer
METABOLISM  Enzyme: CYP3A [HSA:1576 1577 1551]
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01E PROTEIN KINASE INHIBITORS
                L01ED Anaplastic lymphoma kinase (ALK) inhibitors
                 L01ED02 Ceritinib
                  D10551  Ceritinib (JAN/USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Molecular Target Inhibitors
               Ceritinib
                D10551  Ceritinib (JAN/USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D10551  Ceritinib (JAN/USAN/INN)
            Drug groups [BR:br08330]
             Antineoplastic
              DG01918  Tyrosine kinase inhibitor
               DG03136  ALK inhibitor
                D10551  Ceritinib
             Metabolizing enzyme substrate
              DG01633  CYP3A/CYP3A4 substrate
               D10551  Ceritinib
            Drug classes [BR:br08332]
             Antineoplastic
              DG03136  ALK inhibitor
               D10551  Ceritinib
            Target-based classification of drugs [BR:br08310]
             Protein kinases
              Receptor tyrosine kinases (RTK)
               ALK family
                EML4-ALK [HSA_VAR:238v1]
                 D10551  Ceritinib (JAN/USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10551
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10551
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D10551
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10551
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D10551
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D10551
DBLINKS     CAS: 1032900-25-6
            PubChem: 254741513
            PDB-CCD: 4MK
ATOM        38
            1   C1x C     5.6700  -17.9200
            2   N1x N     5.6700  -19.3200
            3   C1x C     6.8824  -20.0200
            4   C1x C     8.0949  -19.3200
            5   C1y C     8.0949  -17.9200
            6   C1x C     6.8824  -17.2200
            7   C8y C     9.3260  -17.2090
            8   C8y C    10.5312  -17.9047
            9   C8x C    11.7435  -17.2046
            10  C8y C    11.7435  -15.8046
            11  C8y C    10.5383  -15.1089
            12  C8x C     9.3259  -15.8090
            13  O2a O    10.5385  -13.7204
            14  C1a C    10.5316  -19.3196
            15  N1b N    12.9614  -15.1012
            16  C8y C    14.1734  -15.8007
            17  N5x N    14.1740  -17.2196
            18  C8x C    15.3867  -17.9190
            19  C8y C    16.5989  -17.2185
            20  C8y C    16.5982  -15.7996
            21  N5x N    15.3855  -15.1002
            22  X   Cl   17.8056  -17.9145
            23  N1b N    17.7954  -15.1079
            24  C8y C    19.0016  -15.8039
            25  C8x C    19.0023  -17.2196
            26  C8x C    20.2151  -17.9190
            27  C8x C    21.4272  -17.2184
            28  C8x C    21.4265  -15.8027
            29  C8y C    20.2137  -15.1033
            30  S4a S    20.2131  -13.7201
            31  O3c O    21.6131  -13.7201
            32  O3c O    18.8131  -13.7201
            33  C1c C    20.2131  -12.3201
            34  C1a C    21.4382  -11.6127
            35  C1a C    19.0134  -11.6274
            36  C1c C     9.3498  -13.0337
            37  C1a C     8.1658  -13.7170
            38  C1a C     9.3498  -11.6203
BOND        41
            1     1   2 1
            2     2   3 1
            3     3   4 1
            4     4   5 1
            5     5   6 1
            6     1   6 1
            7     5   7 1
            8     7   8 2
            9     8   9 1
            10    9  10 2
            11   10  11 1
            12   11  12 2
            13    7  12 1
            14   11  13 1
            15    8  14 1
            16   10  15 1
            17   15  16 1
            18   16  17 2
            19   17  18 1
            20   18  19 2
            21   19  20 1
            22   20  21 2
            23   16  21 1
            24   19  22 1
            25   20  23 1
            26   23  24 1
            27   24  25 2
            28   25  26 1
            29   26  27 2
            30   27  28 1
            31   28  29 2
            32   24  29 1
            33   29  30 1
            34   30  31 2
            35   30  32 2
            36   30  33 1
            37   33  34 1
            38   33  35 1
            39   13  36 1
            40   36  37 1
            41   36  38 1
///
